A Novel Veterinary Molecular Multiplex Microarray Serological Allergen Test (Pet Allergy Xplorer; Nextmune) Versus Conventional Extract-Based Serological (Idexx; Stallergenes Greer Laboratories) Versus Intradermal Allergen Testing in 59 Dogs With Atopic Dermatitis: Evaluation of Agreement Between Allergy Testing Platforms

BACKGROUND: The first veterinary multiplex molecular microarray serum allergy test (SAT), Pet Allergy Xplorer, is commercially available. However, no comparative evaluations of this test versus whole extract-based SAT (eSAT) platforms and intradermal allergen testing (IDAT) currently exist. HYPOTHESIS/OBJECTIVES: Evaluate agreement between IDAT, conventional eSAT (Stallergenes Greer Laboratories) and extract and recombinant-containing SAT (erSAT) for shared environmental allergens in atopic dogs. ANIMALS: Fifty-four dogs with non-seasonal (with or without seasonal exacerbation) and five dogs with seasonal atopic dermatitis were enrolled. MATERIALS AND METHODS: IDAT, eSAT and erSAT were performed on the same day. Two independent investigators (Inv A and Inv B) recorded IDAT results. Per manufacturer guidance, 80 and 300 enzyme-linked immunosorbent assay (ELISA) absorbance units (eSAT80 and eSAT300) and 28 ng/mL (erSAT) were used as SAT cut-off values. Cohen's kappa (κ) and prevalence-adjusted bias-adjusted kappa (PABAK) were used to test agreement. RESULTS: Between IDAT investigators, there was almost perfect agreement across all allergens (κ = 0.81; PABAK = 0.87). Moderate agreement (κ = 0.58) between erSAT and eSAT300 across all allergens improved to almost perfect with PABAK (0.84). IDAT Inv A had the strongest agreement with eSAT300 (κ = 0.44, PABAK = 0.75) compared to erSAT (κ = 0.29, PABAK = 0.64) and eSAT80 (κ = 0.13, PABAK = 0.11); results were similar with Inv B. CONCLUSIONS AND CLINICAL RELEVANCE: Agreement between testing platforms varied depending on the kappa statistic used, with low κ agreement for most comparisons, highlighting disagreements on what was considered positive. PABAK was generally higher, showcasing high overall concordance. Agreement to the new erSAT was strongest with eSAT300; agreement was moderate (κ) to almost perfect (PABAK).

Authors: D. Birchler, M. Austel and F. Banovic Title: A Novel Veterinary Molecular Multiplex Microarray Serological Allergen Test (Pet Allergy Xplorer; Nextmune) Versus Conventional Extract-Based Serological (Idexx; Stallergenes Greer Laboratories) Versus Intradermal Allergen Testing in 59 Dogs With Atopic Dermatitis: Evaluation of Agreement Between Allergy Testing Platforms Full source: Vet Dermatol, 2026,Vol Document type: Journal Article
Résumé, analyse et commentaires
Aucun.
Photo
Aucune.
Analysis
None.
Abstract	Source
BACKGROUND: The first veterinary multiplex molecular microarray serum allergy test (SAT), Pet Allergy Xplorer, is commercially available. However, no comparative evaluations of this test versus whole extract-based SAT (eSAT) platforms and intradermal allergen testing (IDAT) currently exist. HYPOTHESIS/OBJECTIVES: Evaluate agreement between IDAT, conventional eSAT (Stallergenes Greer Laboratories) and extract and recombinant-containing SAT (erSAT) for shared environmental allergens in atopic dogs. ANIMALS: Fifty-four dogs with non-seasonal (with or without seasonal exacerbation) and five dogs with seasonal atopic dermatitis were enrolled. MATERIALS AND METHODS: IDAT, eSAT and erSAT were performed on the same day. Two independent investigators (Inv A and Inv B) recorded IDAT results. Per manufacturer guidance, 80 and 300 enzyme-linked immunosorbent assay (ELISA) absorbance units (eSAT80 and eSAT300) and 28 ng/mL (erSAT) were used as SAT cut-off values. Cohen's kappa (κ) and prevalence-adjusted bias-adjusted kappa (PABAK) were used to test agreement. RESULTS: Between IDAT investigators, there was almost perfect agreement across all allergens (κ = 0.81; PABAK = 0.87). Moderate agreement (κ = 0.58) between erSAT and eSAT300 across all allergens improved to almost perfect with PABAK (0.84). IDAT Inv A had the strongest agreement with eSAT300 (κ = 0.44, PABAK = 0.75) compared to erSAT (κ = 0.29, PABAK = 0.64) and eSAT80 (κ = 0.13, PABAK = 0.11); results were similar with Inv B. CONCLUSIONS AND CLINICAL RELEVANCE: Agreement between testing platforms varied depending on the kappa statistic used, with low κ agreement for most comparisons, highlighting disagreements on what was considered positive. PABAK was generally higher, showcasing high overall concordance. Agreement to the new erSAT was strongest with eSAT300; agreement was moderate (κ) to almost perfect (PABAK).